Ascendis Pharma (NasdaqGS:ASND) is in focus after the U.S. FDA granted accelerated approval for YUVIWEL, a once weekly treatment for children with achondroplasia, along with a Rare Pediatric Disease Priority Review Voucher.

The FDA approval, Rare Pediatric Disease Priority Review Voucher and upcoming conference appearance at the TD Cowen Health Care Conference come alongside a 1 year total shareholder return of 59.34% and a 3 month share price return of 19.75%. These developments suggest momentum has been building around Ascendis Pharma.

If this FDA milestone has you looking at other healthcare names, our screener of 28 healthcare AI stocks is a useful way to spot more specialized opportunities in the sector.

With the shares up strongly over 1 year and trading at US$242.09, alongside an intrinsic value estimate that implies a sizable discount, the key question is whether Ascendis Pharma still offers upside or whether the market is already pricing in future growth.

Most Popular Narrative: 12.7% Undervalued

Ascendis Pharma's most followed valuation narrative points to a fair value of $277.16 versus the last close at $242.09, framing the stock as meaningfully below that estimate.

Regulatory progress and pipeline advancement, such as the priority review for TransCon CNP in achondroplasia and positive combination trial results, are paving the way for new blockbuster therapies and potential multi billion EUR peak sales opportunities, enhancing future revenue growth and reducing revenue concentration risk.

Read the complete narrative. Read the complete narrative.

Want to understand why this story supports a higher fair value? The narrative leans on rapid revenue expansion, a swing to strong profitability, and a richer future earnings multiple. Curious which specific growth and margin assumptions sit underneath that $277.16 figure? The full breakdown lays those expectations out in detail.

Result: Fair Value of $277.16 (UNDERVALUED)

However, this story can change quickly if Yorvipath or Skytrofa uptake falls short of expectations, or if pricing and reimbursement pushback squeezes margins harder than modeled.

Another Angle On Valuation

That 12.7% upside to the US$277.16 fair value is one story, but the market is also valuing Ascendis on a rich P/S of 16.9x. That is higher than both the US Biotechs industry at 12.5x and its own fair ratio of 14.4x, which suggests investors are already paying up for growth. Is that premium comfortable for you, given the execution risks?

Next Steps

Given the mix of optimism around approvals and questions on valuation, it makes sense to look at the full picture yourself and move quickly. A good place to start is by weighing both sides of the story through 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this story has sharpened your focus, do not stop here, the next set of ideas you shortlist could make a real difference to your portfolio.

• Target quality at a discount by scanning our list of 49 high quality undervalued stocks that pair sturdy fundamentals with prices below their estimated worth.
• Build steadier income potential by reviewing 13 dividend fortresses that combine higher yields with an emphasis on resilience.
• Reduce portfolio stress by focusing on 76 resilient stocks with low risk scores that score well on our risk framework and financial strength checks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.